SCHEMBL26640680

SCHEMBL26640680

CN(C)Cc1cccc(Nc2ncc3c(n2)CN(C(=O)OC(C)(C)C)CC3)c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.55
▸ CDK2 P24941 3/20 0.46
▸ AURKA O14965 1/20 0.46
▸ CDK5 Q00535 1/20 0.46
▸ CDK5R1 Q15078 1/20 0.46
▸ CCNA2 P20248 1/20 0.45
▸ CCNA1 P78396 1/20 0.45
▸ FYN P06241 1/20 0.45
▸ CAMK2D Q13557 1/20 0.44
▸ MAPK1 P28482 5/20 0.44
▸ KDR P35968 2/20 0.43
▸ PDGFRB P09619 1/20 0.43
▸ JAK3 P52333 3/20 0.42
▸ JAK2 O60674 2/20 0.42
▸ PTK2 Q05397 2/20 0.42
▸ DDB1 Q16531 1/20 0.42
▸ CRBN Q96SW2 1/20 0.42
▸ MKNK1 Q9BUB5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30648697 1.00 MAPT (0.55) MAPTCDK2AURKACDK5CDK5R1
SCHEMBL26640722 0.90 MAPT (0.63) MAPTCDK2CCNA2CCNA1MAPK1
SCHEMBL30648637 0.88 MAPT (0.53) MAPTCDK2AURKACDK5CDK5R1
SCHEMBL26640702 0.88 MAPT (0.53) MAPTCDK2AURKACDK5CDK5R1
SCHEMBL26640288 0.88 MAPT (0.55) MAPTCDK2CDK5CDK5R1FYN
SCHEMBL30648780 0.88 MAPT (0.55) MAPTCDK2CDK5CDK5R1FYN
SCHEMBL30648709 0.85 MAPT (0.52) MAPTCDK2AURKACDK5CDK5R1
SCHEMBL26640682 0.85 MAPT (0.52) MAPTCDK2AURKACDK5CDK5R1
SCHEMBL30648732 0.84 MAPT (0.58) MAPTCDK2CDK5CDK5R1CCNA2
SCHEMBL26640403 0.84 MAPT (0.58) MAPTCDK2CDK5CDK5R1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
WO-2023220541-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS MERCK PATENT GMBH (DE) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS PDXK, DTYMK, HIPK1 MAPT 3283/4885CDK2 257/4885AURKA 483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback